Extended interval dosing of gentamicin in premature neonates ≤ 28-week gestation

Acta Paediatr. 2012 Nov;101(11):1134-9. doi: 10.1111/j.1651-2227.2012.02820.x. Epub 2012 Sep 7.

Abstract

Aim: To evaluate an extended interval dosing (EID) regimen of gentamicin in neonates ≤28-week gestation.

Methods: In 2008, an EID regimen for gentamicin was introduced for all neonates admitted to the NICU in Calgary. The dosing interval was based on a 22 h level after the first dose of 5mg/kg. We conducted an observational study in 33 infants ≤28-week gestation on the EID regimen from the first day of life and compared gentamicin peak and trough levels with a historical control of 34 infants who received gentamicin in a dose of 2.5 mg/kg every 24 h (TID, traditional interval dosing).

Results: In the EID group, based on the 22 h level, dosing interval was 36 h in 20 neonates and 48 h in 13 neonates. All neonates, except one, achieved therapeutic peak and trough levels. Compared to the TID group, the EID group had higher peak levels (median 9.8 μg/mL vs. 4.6 μg/mL, p < 0.001) with no difference in trough levels. With target peak levels of 5-12 μg/mL and trough levels of <2 μg/mL, a higher proportion of neonates in the TID group would need dose adjustment.

Conclusion: In neonates ≤ 28-week gestation, an EID regimen from day one of life, using a single level 22 h after the first dose for dosing interval, achieves therapeutic peak and trough levels and more optimum peak levels as compared to a TID regimen.

Publication types

  • Comparative Study
  • Evaluation Study

MeSH terms

  • Anti-Bacterial Agents / administration & dosage*
  • Anti-Bacterial Agents / blood
  • Anti-Bacterial Agents / pharmacokinetics
  • Anti-Bacterial Agents / therapeutic use
  • Drug Administration Schedule
  • Female
  • Gentamicins / administration & dosage*
  • Gentamicins / blood
  • Gentamicins / pharmacokinetics
  • Gentamicins / therapeutic use
  • Humans
  • Infant, Newborn
  • Infant, Premature
  • Infant, Premature, Diseases / blood
  • Infant, Premature, Diseases / drug therapy*
  • Male
  • Retrospective Studies
  • Sepsis / blood
  • Sepsis / drug therapy*
  • Treatment Outcome

Substances

  • Anti-Bacterial Agents
  • Gentamicins